Capital Research Global Investors
PRAX icon

Capital Research Global Investors’s Praxis Precision Medicines PRAX Stock Holding History

Capital Research Global Investors’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-853,746
Closed -$32.3M – 464
2025
Q1 		$32.3M Sell
853,746
-139,823
-14% -$8.73M 0.01% 381
2024
Q4 		$76.5M Sell
993,569
-3,525
-0.4% -$255K 0.02% 326
2024
Q3 		$57.4M Buy
+997,094
New +$53.9M 0.01% 328

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital Research Global Investors's PRAX Position: Q2 2025 in Review

Capital Research Global Investors sold out of Praxis Precision Medicines (PRAX) in Q2 2025, closing a stake of 853,746 shares — an estimated $32.3M sold.

Capital Research Global Investors first reported a position in PRAX in Q3 2024 and held it in 3 quarters. The position peaked at $76.5M in Q4 2024. 143 funds tracked by Wall St. Rank hold PRAX as of Q2 2025.

  • Capital Research Global Investors reported no remaining Praxis Precision Medicines position as of Q2 2025 after selling out during the quarter.
  • Capital Research Global Investors sold 853,746 Praxis Precision Medicines shares in Q2 2025, an estimated $32.3M.
  • Capital Research Global Investors first reported a position in Praxis Precision Medicines in Q3 2024 and held it in 3 quarters.
  • Capital Research Global Investors's Praxis Precision Medicines position peaked at $76.5M in Q4 2024.
  • 143 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2025.

Based on Capital Research Global Investors's 13F filing for Q2 2025, filed 13 Aug 2025.